Over-expression of PD-L1 in malignancies induces T cell failure via PD-1/PD-L1 signaling pathway, allowing tumor cells to evade host immune surveillance and T cell immune attack, thus leading to poor clinical prognosis and cancer recurrence [23]. The gene discussed is RPL17; the disease is neoplasm.